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cancer Patients
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Emma Foley1, John V. Reynolds1,3, Aideen Long4 and Joanne Lysaght1*
1 Department of Surgery, St. James’s Hospital, Trinity College Dublin, Trinity Translational Medicine Institute, Dublin, Ireland, 
2 School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland, 3 Gastro-Intestinal Medicine and Surgery, 
St. James’s Hospital, Dublin, Ireland, 4 Department of Clinical Medicine, St. James’s Hospital, Trinity College Dublin, Trinity 
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The omentum is enriched with pro-inflammatory effector memory CD8+ T  cells in 
patients with the obesity-associated malignancy, esophagogastric adenocarcinoma 
(EAC) and we have identified the chemokine macrophage inflammatory protein-1alpha 
as a key player in their active migration to this inflamed tissue. More recently, others 
have established that subsets of memory CD8+ T cells can be classified based on their 
surface expression of CX3CR1; the specific receptor for the inflammatory chemokine 
fractalkine. CD8+ T  cells expressing intermediate levels (CX3CR1INT) are defined as 
peripheral memory, those expressing the highest levels (CX3CR1HI) are effector memory/
terminally differentiated and those lacking CX3CR1 (CX3CR1NEG) are classified as central 
memory. To date, the fractalkine:CX3CR1 axis has not been examined in the context of 
CD8+ T cell enrichment in the omentum and here we examine this chemokines involve-
ment in the accumulation of memory CD8+ T cells in the omentum of EAC patients. 
Our data show that fractalkine is significantly enriched in the omentum of EAC patients 
and drives migration of T cells derived from EAC patient blood. Furthermore, CX3CR1 
is endocytosed specifically by CD8+ T  cells upon encountering fractalkine, which is 
consistent with the significantly diminished frequencies of CX3CR1INT and CX3CR1HI 
CD8+ T cells in the fractalkine-rich environment of omentum in EAC, relative to matched 
blood. Fractalkine-mediated endocytosis of CX3CR1 by CD8+ T cells is sustained and 
is followed by enhanced surface expression of L-selectin (CD62L). These novel data 
align with our findings that circulating CX3CR1NEG CD8+ T cells express higher levels 
of L-selectin than CX3CR1INT CD8+ T cells. This is consistent with previous reports and 
implicates fractalkine in the conversion of CX3CR1INT CD8+ T cells to a CX3CR1NEG phe-
notype characterized by alterations in the migratory capacity of these T cells. For the first 
time, these findings identify fractalkine as a driver of T cell migration to the omentum in 
EAC and indicate that CD8+ T cells undergo sequenced fractalkine-mediated alterations 
in CX3CR1 and L-selectin expression. These data implicate fractalkine as more than a 
chemotactic cytokine in obesity-associated meta-inflammation and reveal a role for this 
chemokine in the maintenance of the CX3CR1NEG CD8+ T cell populations.
Keywords: fractalkine, cX3cr1, T cells, obesity, upper gastrointestinal cancer, inflammation, adhesion, omentum
TaBle 1 | Demographic data.
Age (range years) 65.9 (35–93)
Sex ratio (M:F) 37:10
Esophageal adenocarcinoma 38
Gastric adenocarcinoma 9
Tumor stagea
T0 4
T1 11
T2 8
T3 20
T4 1
Nodal statusa
Positive 21
Negative 23
Mean BMI (kg/m2) (range)b 26.4 (17.8–36.4)
Underweight (BMI < 19.9) 4
Normal weight (BMI 20–24.9) 12
Overweight (BMI 25–29.9) 13
Obese (BMI > 30) 14
Mean waist circumference (cm) (range) 93.8 (68–115)
Centrally obese by waist circumferencec 57.75%
Mean visceral fat area (VFA) (cm2) (range) 126.54 (4.65–353.05)
Viscerally obese by VFAd 30%
Received Neoadjuvant CRT 81%
aTumor stage and nodal status was not available for three patients.
bBMI was not available for four patients.
cObese waist circumference ≥94 cm for men and ≥80 cm for women (25).
dObese VFA >160 cm2 for men and >80 cm2 for women (24).
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at a time when the global obesity problem has reached epidemic 
proportions and shows no signs of abating (www.who.int).
For the first time, this study identifies a role for fractalkine 
in the recruitment of T cells to the inflamed omentum of EAC 
patients implicating this chemokine as a player and potential 
therapeutic target in pathological T cell-mediated inflammation 
in obesity and obesity-associated malignancies. Importantly, our 
data also reveal fractalkine-mediated regulation of CX3CR1 and 
L-selectin expression by CD8+ T cells, placing this inflammatory 
chemokine as an orchestrator of cytotoxic T cell trafficking and 
memory in EAC. The data generated here has ramifications for 
fractalkine as a therapeutic target for inflammation particularly 
in the context of cancer indicating that antagonism of this path-
way might have consequences for L-selectin-dependent cytotoxic 
T cell homing to lymph nodes and anti-tumor immunity.
MaTerials anD MeThODs
subjects
Forty-seven consecutive consenting patients with EAC, attend-
ing the National Esophageal and Gastric Center at St. James’s 
Hospital, Dublin from 2011 to 2018 were enrolled in this study. 
The patient cohort was similar in age and ethnicity, and 81% had 
received neoadjuvant chemo-radiotherapy. The patient group 
included 37 males and 10 females, representative of the male pre-
dominance in EAC, with an average age of 65.9 years. The mean 
BMI at time of surgery was 26.4 and CT-defined visceral fat area 
(VFA) was 126.54 cm2 (Table 1). Control blood and omentum 
were taken from a group of non-cancer control patients attending 
St. James’s Hospital, Dublin for laparoscopic cholecystectomy. All 
inTrODUcTiOn
The flexibility and multifaceted functionality of chemokines 
together with their involvement in multiple inflammatory 
diseases has ignited an interest in their potential as targets 
for immunotherapy (1, 2). Indeed, there has been a paradigm 
shift in the classification of chemokines as solely chemotactic 
cytokines and emerging evidence has uncovered their additional 
functions in the generation of effector and memory T cells and 
the co-stimulation of cytokine secretion by T cells (3–5). Most 
recently, the specific receptor for the inflammatory chemokine 
fractalkine, CX3CR1 has been used to classify memory CD8+ 
T cell subsets (5).
Fractalkine (CX3CL1) exists in both a soluble and transmem-
brane form, and plays a role in both immune cell migration and 
adhesion and has been implicated in multiple inflammatory 
diseases such as asthma, dermatitis, diabetes, and neuropathic 
pain (6–12). The involvement of this chemokine in several 
inflammatory disorders is facilitated through its induction by 
inflammatory cytokines such as TNF-α, IFN-γ, and IL-1 (13). In 
the context of obesity, fractalkine has already been implicated in 
obesity-associated diseases such as diabetes and cardiovascular 
disease and in the chronic inflammation that precedes metabolic 
dysfunction; meta-inflammation (7, 8, 10, 14). Fractalkine is 
known to be expressed by endothelial cells and facilitates vascular 
recruitment and adhesion of macrophages, NK cells, and T cells, 
however, its expression by both the stromal vascular fraction 
(SVF) and the adipocyte fraction has been demonstrated in the 
adipose tissue (8). Most studies have focused on the role of frac-
talkine in macrophage-mediated adipose tissue inflammation (8, 
15, 16), with previous work demonstrating a role for fractalkine 
in macrophage recruitment and macrophage-adipocyte adhesion 
in adipose tissue but, to our knowledge there are no reports of 
fractalkine-driven migration of T cells in obesity (8).
The omentum forms the largest component of the visceral adi-
pose tissue (VAT) compartment and is enriched with leukocyte 
aggregates which liken it to the follicles of secondary lymphoid 
tissues and promote immune responses and inflammation (17). 
We have previously shown that the omentum is a hot bed of 
T cell-mediated inflammation in patients with esophagogastric 
adenocarcinoma (EAC), a malignancy that arises in a back-
ground of inflammation and importantly has one of the strongest 
associations with obesity of all malignancies (18). Furthermore, 
we have identified the macrophage inflammatory protein-1alpha 
(MIP-1α)/CCR1 axis as a key pathway governing T cell migration 
to the omentum of EAC patients and reported its therapeutic 
potential in the space of obesity-associated inflammation (19). 
However, the fractalkine pathway may present a more attractive 
and more specific therapeutic target in this setting as there is only 
one known receptor for this chemokine (CX3CR1), in contrast 
to the redundancy observed in other chemokine pathways (1, 20, 
21). We have already demonstrated that the omentum of EAC 
patients is primed for fractalkine-mediated inflammation through 
an abundance of TNF-α-producing CD8+ and CD4+ T cells and 
secreted IL-1β and here, we address the role of fractalkine in 
inflammatory and cytotoxic T cell trafficking and retention in this 
inflamed tissue (22, 23). These questions are extremely relevant 
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cancer patients were evaluated by a dietician. Body mass index, 
waist circumference, and anthropometric variables were meas-
ured as described previously (23). VFA was assessed by computer 
tomography as previously described, with more than 160 and 
80 cm2 defining visceral obesity in males and females, respectively 
(24). Serum C-reactive protein (CRP) levels were determined as 
part of routine testing at time of surgery. Metabolic syndrome was 
measured as per the IDF definition (25).
ethics approval statement
The work was performed in accordance with The Code of Ethics 
of the World Medical Association (Declaration of Helsinki) for 
experiments involving humans. Patients provided informed 
consent for sample and data acquisition and the study received 
full ethical approval from the St. James’s Hospital Ethics Review 
Board. Patient samples were pseudonymized to protect the pri-
vacy rights of the patients.
sample Preparation
Peripheral blood mononuclear cells (PBMC) were isolated by 
density centrifugation using Ficoll-Paque™ Plus (GE Healthcare, 
Uppsala, Sweden). Omental samples (10 g from each patient) were 
digested enzymatically to obtain SVF as previously described (22, 
23). Adipose tissue conditioned media (ACM) was prepared as 
previously described (22).
Quantification of soluble Fractalkine and 
cX3cr1 levels in serum and Omentum
The V-PLEX™ Fractalkine plate (Meso Scale Discovery) was 
used to detect the levels of fractalkine in the serum and ACM 
of 19 EAC patients according to the manufacturer’s instructions 
and read using an MSD Sector S600. The Human CX3CR1 ELISA 
Kit (ELISA Genie) was used to measure secreted CX3CR1 in the 
serum and ACM of 10 EAC patients and read using a VersaMax™ 
ELISA microplate reader.
examining secreted adhesion Molecule 
levels in the Omentum of eac Patients
The Evidence Investigator Adhesion Molecules Array (RANDOX) 
was used to detect the concentrations of VCAM-1, ICAM-1, 
L-selectin, P-selectin, and E-selectin in the ACM of five EAC 
patients according to the manufacturer’s instructions and read 
using a RANDOX Evidence Investigator.
T cell chemotaxis assays
To activate the T cells for chemotaxis, PBMC were prepared from 
the blood of five EAC patients and three non-cancer controls, and 
incubated with CD3/CD28 T-cell expander Dynabeads (Invitrogen) 
at a bead:cell ratio of 1:1. Following activation, the beads were 
removed and the T cells were counted and resuspended at densi-
ties of 2 × 106 cells/ml serum-free RPMI media. Chemotaxis was 
assessed using a 5-µm pore transwell filter system (Corning Inc., 
USA). Cells were added to the top chamber in a volume of 100 µl 
RPMI, while the bottom chamber contained 600 µl of the following; 
M199 media alone (negative control) or M199 media supplemented 
with fractalkine at a concentration of 30 ng/ml (based on the mean 
concentration in EAC ACM) or ACM derived from four obese and 
three non-obese EAC patients or ACM derived from two obese and 
three non-obese non-cancer controls. The assay was incubated for 
2 h at 37°C before removal of the insert. The media in the bottom 
chambers were taken and centrifuged at 1,300 RPM for 3 min and 
then stained for CD3 expression. CountBright Absolute Counting 
Beads (Invitrogen) were used to enumerate the absolute number of 
CD3+ T cells that had migrated.
Quantification of cX3cr1 expressing 
T cells in Blood and Omentum and 
Phenotyping of cX3cr1neg and cX3cr1inT 
cD8+ T cell Populations
Freshly isolated PBMC and SVF were stained with monoclonal 
antibodies specific for human surface markers; PE-efluor-labeled 
CD3 and APC-eFluor780-labeled CD27 (eBioscience, Hatfield, 
UK), PE-Cy5.5-labeled CD4, APC-labeled ICAM-1 (CD54), 
V500-labeled CD45RA, and BV421-labeled CD8 (BD Biosciences, 
Oxford, UK), PE-Cy5-labeled L-selectin (Abcam, Cambridge, 
UK), and PE-labeled CX3CR1 (Miltenyi Biotec, Germany). 
Cells were acquired using CyAn ADP flow cytometer (Beckman 
Coulter) and analyzed with FlowJo software (TreeStar Inc.).
cX3cr1 surface expression by T cells 
Following recombinant Fractalkine 
Treatment
To examine the effects of fractalkine on CX3CR1 expression by 
CD8+ T cells, PBMC from 17 EAC patients were seeded in RPMI 
media at 1 × 106 cells/ml and treated with M199 media or 30 ng/
ml of recombinant fractalkine for 15 min, 30 min, 1 h, 2 h, and 24 h 
and subsequently analyzed for CX3CR1 surface expression using 
flow cytometry, as described above. To test whether CX3CR1 was 
endocytosed, PBMC from 10 EAC patients were treated with M199 
media (untreated) or 30 ng/ml of recombinant fractalkine for 2 h 
at 4°C (cold treatment) or in the presence of 80 µM of the GTPase 
inhibitor dynasore (Sigma Aldrich). To examine whether CX3CR1 
is recycled to the surface of CD8+ T  cells following fractalkine 
treatment, PBMC from three donors were seeded in RPMI media 
at 1 × 106 cells/ml and treated with M199 media alone or 30 ng/ml 
of recombinant fractalkine for 2 h. Following 2 h, cells were washed 
and placed in fractalkine-free media for 24 and 48 h or placed in 
fractalkine-free media supplemented with 50 ng/ml of TNF-α or 
100  ng/ml of IFN-γ, IL-6, IL-7, IL-17, IL-18, IL-15, or IL-36 or 
50 U/ml of IL-2 for 24 h and subsequently analyzed for CX3CR1 
surface expression using flow cytometry.
examining cX3cr1 Protein expression 
Following Treatment With recombinant 
Fractalkine
CD8+ T  cells from three healthy control subjects were isolated 
from PBMC using the EasySep™ Human CD8+ T Cell Isolation 
Kit (Stemcell Technologies) and subsequently seeded at a density 
of 1 ×  106 cells/ml RPMI media and treated with 30  ng/ml of 
fractalkine for 24 and 48 h. Flow cytometry was used to confirm 
reduction of CX3CR1 surface expression on a subset of treated 
FigUre 1 | Both soluble fractalkine and CX3CR1 are secreted in abundance in the omentum of esophagogastric adenocarcinoma (EAC) patients and fractalkine 
can drive migration of EAC patient-derived T cells. (a) Scatter plots showing the fractalkine (top) and soluble CX3CR1 levels (bottom) in paired samples of serum 
and adipose tissue conditioned media (ACM) from 10 to 19 EAC patients. (B) Bar charts showing significant fold change migration of peripheral blood-derived 
T cells from five EAC patients to M199 media supplemented with 30 ng/ml of recombinant fractalkine, relative to M199 alone negative control. (c) Bar charts 
showing the levels of soluble VCAM-1, ICAM-1, E-selectin, P-selectin, and L-selectin in omental adipose tissue conditioned media (ACM) from five EAC patients. (D) 
Bar charts showing the fractalkine levels in serum and ACM from 3 non-cancer control subjects and 20 EAC patients, from 9 non-obese and 11 obese EAC 
patients, and 17 EAC patients with serum C-reactive protein (CRP) <5 mg/l (low CRP) and 3 EAC patients with serum CRP >5 mg/l (high CRP). (e) Bar charts 
showing significant fold change migration of peripheral blood-derived T cells to ACM from three non-obese and four obese EAC patients and three non-obese and 
two obese non-cancer controls. *p < 0.05, **p < 0.01, ***p < 0.001 by paired, unpaired t tests and one-way ANOVA with Tukey post hoc analysis.
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TaBle 2 | Correlations of CX3CL1 levels and frequencies of CX3CR1NEG 
expressing T cells with waist circumference, visceral fat area (VFA), and body 
mass index.
R2 values for correlations of 
cX3cr1 and the following 
measurements
Waist 
circumference
R2 value
VFa
R2 value
Body mass 
index
R2 value
Serum CX3CL1 0.028 0.058 0.119
Omental CX3CL1 0.003 0.126 0.134
Peripheral CX3CR1+ CD4+ T cells −0.15 0.008 −0.054
Omental CX3CR1+ CD4+ T cells 0.193 0.159 0.036074
Peripheral CX3CR1+ CD8+ T cells −0.298 −0.216 −0.164
Omental CX3CR1+ CD8+ T cells 0.464 0.044 0.073
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and untreated cells after 24 h and the remainder of the cells were 
lysed. Protein was extracted using a 6 M urea lysis buffer (15 min 
on ice). Protein was quantified against a standard curve using the 
Pierce BCA Protein Assay Kit (Thermofisher). Protein (60 µg per 
sample) was loaded onto a 10% SDS page gel and electrophoresed 
for 80 min. Separated protein was subsequently transferred to a 
PVDF membrane. Membrane was blocked in 0.5% Bovine Serum 
Albumin (in TBST) for 1.5 h at room temperature. The membrane 
was incubated for 1.5  h at room temperature with mouse anti-
human CX3CR1 antibody (H-70) (Santa Cruz) at 1:1,000 dilution 
in 0.5% BSA TBST. The membrane was incubated for 1 h at room 
temperature with secondary antibody (goat anti-mouse IgG-HRP 
at 1:5,000 dilution in 0.5% BSA TBST). Bands were visualized using 
the West Pico chemiluminescent substrate on a gel doc. Beta-actin 
primary mouse anti-human at 1:10,000 dilution (Santa Cruz) was 
used as a loading control. Protein extract quality was confirmed 
visually via coomassie blue staining (10% gel, 20 µg protein per 
sample). CD8+ T cells from three control subjects were isolated 
from PBMC using the EasySep™ Human CD8+ T Cell Isolation Kit 
(Stemcell Technologies) and subsequently seeded in RPMI media 
at 1 × 106 cells/ml and treated with 30 ng/ml of fractalkine for 24 
and 48 h. Cell supernatant was collected after 24 and 48 h and the 
Human CX3CR1 ELISA Kit (ELISA Genie) was used to compare 
secreted CX3CR1 in the untreated and fractalkine-treated cells.
assessing integrin and adhesion Molecule 
expression Together With Memory 
Phenotype of cD8+ T cells Following 
Fractalkine Treatment
To examine the effects of fractalkine on CX3CR1 expression by 
CD8+ T  cells, PBMC from six EAC patients were treated with 
M199 media alone or M199 media supplemented with 30 ng/ml 
of recombinant fractalkine for 24 h and subsequently analyzed 
for VLA-4, LFA-1, alpha4 integrin, beta7 integrin, ICAM-1, 
L-selectin, CD45RA, and CD27 surface expression using flow 
cytometry, as described above.
statistical analyses
Statistical analysis was carried out using Prism GraphPad Version 
5.0. Differences between groups were assessed using two-tailed 
paired, Wilcoxon sign-rank test, unpaired non-parametric 
Mann–Whitney U tests, and one-way ANOVA with Tukey post hoc 
analysis where appropriate. Significant associations between 
fractalkine, CX3CR1, and clinical parameters were investigated 
using Spearman’s rank-order correlation test. p Values of <0.05 
were considered to be significant.
resUlTs
significantly high levels of soluble 
Fractalkine in the Omentum of eac 
Patients can Drive Migration of eac 
Patient-Derived T cells
Secreted fractalkine was quantified by MSD V-Plex ELISA in the 
matched serum and omental adipose tissue conditioned media 
(ACM) of 19 EAC patients revealing that levels of this chemokine 
were significantly higher in ACM (mean: 23.66 ng/ml) compared 
to serum (mean: 10.56 ng/ml) (p < 0.001, Figure 1A). Soluble 
CX3CR1 ELISA revealed that the soluble form of the fractalkine 
receptor was also significantly abundant in the ACM of 10 EAC 
patients, compared to matched serum suggesting that the frac-
talkine receptor can be shed in the omental microenvironment 
(mean: 18.1 versus 9.3 ng/ml, p < 0.01, Figure 1A). To confirm 
whether T cells respond and migrate toward fractalkine-elicited 
chemotactic signals in EAC, patient-derived T  cell chemotaxis 
to 30 ng/ml of fractalkine was measured using a transwell sys-
tem. Significantly higher fold-levels of T cell migration toward 
recombinant fractalkine, compared to serum-free M199 media 
were observed supporting our hypothesis of fractalkine-driven 
T cell migration to omentum in EAC (M199 versus fractalkine 
fold change: 1 versus 2.456, p < 0.05, Figure 1B). An adhesion 
molecule array was used to screen omentum-derived ACM from 
five EAC patients for soluble adhesion molecules and ICAM-1 
and L-selectin were shown to be most abundant, indicative 
of the adhesive properties of the omental microenvironment 
(Figure 1C). Secreted fractalkine levels were significantly higher 
in omentum compared to matched serum regardless of patient 
obesity status and interestingly, there were significantly higher 
levels of soluble fractalkine in the omentum of EAC patients 
with elevated serum CRP, i.e., >5 mg/l compared to those with 
lower serum CRP, i.e., <5 mg/l (mean: 65.8 versus 13.87 ng/ml, 
p <  0.05) (Figure  1D; Table  2). Furthermore, our data show 
significant levels of T cell migration to ACM in both non-cancer 
and EAC patients, irrespective of obesity status (Figure 1E).
low Frequencies of cX3cr1+ cD8+ 
T cells in the Omentum of eac Patients 
are due to significantly Diminished 
Frequencies of Both the cX3cr1inT and 
cX3cr1hi subsets of cD8+ T cells
The frequencies of CD4+ and CD8+ T  cells expressing the 
chemokine receptor CX3CR1 were examined in the blood and 
omentum of a total of 24 EAC patients by flow cytometry. Our 
results identified significantly higher frequencies of CX3CR1+ 
CD8+ T  cells in the circulation compared to their CD8+ coun-
terparts in omentum (blood versus omentum mean: 48.87 versus 
23.64%, p = 0.0002, Figure 2A) and compared to proportions of 
FigUre 2 | Frequencies of CX3CR1+ CD8+ T cells are significantly lower in omentum of esophagogastric adenocarcinoma (EAC) patients compared to frequencies 
of both peripheral blood CX3CR1+ CD8+ T cells and CX3CR1+ CD4+ T cells. Peripheral blood mononuclear cells and stromal vascular fraction of omentum were 
isolated from EAC patients. (a) Scatterplots show the frequencies of CX3CR1+ CD8+ and CD4+ T cells in the blood and omentum of a total of 24 EAC patients.  
(B) Representative dot plots of CX3CR1+ CD8+ and CX3CR1+ CD4+ T cells (gated on and shown as a percentage of total CD3+ population) in blood and omentum. 
(c) Bar chart showing the frequencies of CD8+ cells expressing no CX3CR1 (CX3CR1NEG), intermediate (CX3CR1INT), and high levels of CX3CR1 (CX3CR1HI) in the 
blood (white) and omentum (black) of 24 EAC patients. (D) Representative dot plot of circulating CD8+ T cells expressing no CX3CR1 (CX3CR1NEG), intermediate 
levels of CX3CR1 (CX3CR1INT), and high levels of CX3CR1 (CX3CR1HI). (e) Bar charts showing the CX3CR1+ CD8+ and CD4+ T cells in the blood and omentum of 8 
non-cancer control subjects and 24 EAC patients (left) and 14 non-obese and 10 obese EAC patients (right). *p < 0.05, *p < 0.01, ***p < 0.001 by paired and 
unpaired t tests.
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FigUre 3 | Peripheral blood CD8+ T cells exhibit a significant and sustained reduction in CX3CR1 surface expression following treatment with recombinant 
fractalkine. (a) Frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells (left) and CD4+ T cells (right) following; treatment with M199 media alone (NT) or 
30 ng/ml of recombinant fractalkine for 2 h (n = 17); (B) representative dot plots of CX3CR1 expression following treatment with M199 media alone (NT) or 30 ng/ml 
of recombinant fractalkine for 2 h. (c) Frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following treatment with M199 media alone (NT) or 30 ng/ml 
of recombinant fractalkine across a time course of 15 min, 30 min, 1 h, 2 h, or 24 h (n = 4). ***p < 0.001 by paired t tests.
7
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circulating CX3CR1+ CD4+ T cells (mean: 14.48%, p <  0.0001, 
Figure 2A). These differences were paralleled by substantially but 
not significantly higher frequencies of CX3CR1+ CD4+ T  cells 
in EAC omentum (mean: 30.76%, Figures  2A,B) compared to 
blood. Further analysis revealed that the diminished numbers 
of CX3CR1+ CD8+ T  cells within the omentum were due to 
significantly lower frequencies of CD8+ T  cells expressing both 
intermediate and high levels of CX3CR1 and significantly higher 
frequencies of CX3CR1NEG populations in omentum, compared to 
blood (blood versus omentum mean of CX3CR1NEG: 60.24 versus 
81.03%, p <  0.01, CX3CR1INT: 36.34 versus 18.25%, p <  0.01, 
CX3CR1HI: 3.41 versus 0.72%, p < 0.05, Figure 2C). The highest 
proportions of circulating CX3CR1+ cells were identified within 
the CX3CR1INT CD8+ T  cell population (Figures  2C,D). While 
such observations in CX3CR1 expression by T cells were consistent 
among obese and non-obese EAC patients, there were significantly 
higher frequencies of CX3CR1+ CD8+ T cells in the circulation 
of non-cancer controls, compared to EAC patients (non-cancer 
versus EAC: 70.33 versus 48.87%, p < 0.05, Figure 2E; Table 2).
cX3cr1 expression by Peripheral Blood 
but not Omental cD8+ T cells is 
significantly Diminished Following 
Treatment With recombinant Fractalkine
To ascertain why enrichments of CX3CR1+ CD4+ T  cells were 
detected in the omentum, while highest frequencies of CX3CR1+ 
CD8+ T cells were detected in the circulation, we assessed whether 
CX3CR1+ CD8+ T  cells convert to CX3CR1NEG CD8+ T  cells 
upon encountering their ligand, which is secreted in abundance 
in the omental microenvironment. Blood-derived T  cells from 
17 EAC patients were treated with M199 media or recombinant 
fractalkine for 2 h to simulate the effects of the high fractalkine 
levels in the omental microenvironment. Flow cytometric analy-
sis revealed that surface expression of CX3CR1 was significantly 
decreased on peripheral blood CD8+ but not CD4+ T  cells or 
omental CD8+ T cells following 2 h treatment with recombinant 
fractalkine (untreated versus treated CD8+ T  cells: 52.2 versus 
4.238, p = 0.0001, Figures 3A,B). Further analysis revealed that 
CX3CR1 expression by peripheral blood CD8+ T cells is reduced 
between 15 and 30  min post-treatment with most significant 
reductions observed at 2 and 24  h post-treatment (Figure  3C, 
p <  0.001). Fractalkine treatments performed at a temperature 
of 4°C or in combination with treatment of 80 µM dynasore, a 
GTPase inhibitor, demonstrated significantly reduced efficacy to 
decrease CX3CR1 expression on CD8+ T cells thus confirming 
that the observed reductions were due to endocytosis (Figure 4A).
cX3cr1 internalization by cD8+ T cells is 
sustained Following Treatment With 
recombinant Fractalkine and the 
receptor is not Degraded or recycled to 
the cell surface
Surface expression of CX3CR1 by CD8+ T cells was not restored 
when 2 h treatment with fractalkine was followed by culture 
FigUre 4 | Continued
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FigUre 4 | CX3CR1 is endocytosed following fractalkine treatment and is not subsequently recycled to the surface of CD8+ T cells or secreted but, intracellular 
accumulations of the protein are detectable. (a) Frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following treatment with M199 media alone (NT), 
30 ng/ml recombinant fractalkine alone (treatment alone), 30 ng/ml recombinant fractalkine at 4°C and 30 ng/ml recombinant fractalkine plus 80 µM Dynasore 
(n = 10). (B) Bar chart showing frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following treatment with M199 media alone (NT) or 30 ng/ml of 
recombinant fractalkine for 24 h (fractalkine, light gray dot pattern) followed by removal from a fractalkine-free environment for 24 h (fractalkine, dark gray no 
pattern) or 48 h (fractalkine, light gray no pattern) (n = 6). (c) Bar chart showing frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following 
treatment with M199 media alone (NT) or 30 ng/ml of recombinant fractalkine for 24 h (fractalkine, light gray dot pattern) followed by removal from a fractalkine-
free environment for 24 h and treatment with 50 ng/ml of TNF-α, 100 ng/ml of IFN-γ, IL-17, IL-6, IL-7, IL-15, IL-18, IL-36, and 50 U/ml of IL-2 (n = 3). (D) Western 
Blot (left) showing CX3CR1 and beta-actin protein in peripheral blood-derived CD8+ T cells from three donors following 24 h of no treatment (N1, N2, and N3) or 
fractalkine treatment (F1, F2, and F3) and densitometry data (right) from this western blot displayed as fold change bar chart. (e) Soluble CX3CR1 levels in the 
supernatant of peripheral blood mononuclear cells treated with M199 alone or fractalkine for 24 or 48 h (n = 3). *p < 0.05, **p < 0.01 by paired t-test.
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in fractalkine-free media for 24 and 48 h, suggesting that the 
receptor is not recycled to the surface following endocytosis 
(Figure 4B). Stimulation with 50 ng/ml of TNF-α or 100 ng/ml 
of IFN-γ, IL-6, IL-7, IL-17, IL-18, IL-15, or IL-36 or 50 U/ml 
of IL-2 for 24  h following removal of fractalkine, did not 
induce recycling of CX3CR1 to the surface of CD8+ T  cells 
(Figure  4C). Western blot revealed that there are consistent 
accumulations of CX3CR1 protein levels in CD8+ T  cells 
following 24  h fractalkine treatment compared to untreated 
CD8+ T cells demonstrating that the receptor is not degraded 
following fractalkine-mediated endocytosis (Figure  4D). 
Furthermore, ELISA revealed that the levels of CX3CR1 shed 
by T cells are not increased following 24 or 48 h of fractalkine 
treatment (Figure 4E).
cX3cr1neg and cX3cr1inT Populations of 
cD8+ T cells in the Peripheral Blood have 
significantly Different Memory Phenotype 
and adhesion Molecule expression
Since the CX3CR1+ compartments of CD8+ T  cells were 
predominantly CX3CR1INT and this subpopulation has been 
shown to have the potential to convert to CX3CR1NEG CD8+ 
T cells, we focused our phenotypical comparisons between this 
subset and the CX3CR1NEG CD8+ T cell subset [Figure 2C; (5)]. 
Significant differences in memory phenotype were identified 
between the CX3CR1NEG and CX3CR1INT CD8+ T  cells based 
on their CD45RA and CD27 surface expression using the Dieli 
scheme; terminally differentiated (CD45RA+CD27−), naive 
(CD45RA+CD27+), effector memory (CD45RA−CD27−), and 
central memory (CD45RA−CD27+) (26). Our data revealed that 
circulating CX3CR1INT CD8+ T cells were significantly different 
to CX3CR1NEG CD8+ T cells in memory phenotype; CX3CR1INT 
CD8+ T cells were predominantly central memory and effector 
memory phenotype while CX3CR1NEG CD8+ T cells contained 
more naive and terminally differentiated cells (Figure  5A, 
central memory: p  =  0.0001, effector memory: p  <  0.05, 
naive: p =  0.001, terminally differentiated: p =  0.002). These 
phenotypical differences were attributable to significantly lower 
CD45RA surface expression and significantly higher CD27 sur-
face expression within the CX3CR1INT CD8+ T cell population 
(CX3CR1INT versus CX3CR1NEG CD45RA: 27.2 versus 96.4%, 
p < 0.001, CD27, 94.9 versus 68.8%, p < 0.05, Figure 5B). To 
elucidate whether our data compared to previous reports of 
lower L-selectin surface expression within CX3CR1INT T  cell 
population, we examined the expression of L-selectin and 
ICAM-1 on circulating CX3CR1NEG and CX3CR1INT CD8+ 
T  cells (5). Our data revealed significantly lower frequencies 
of ICAM-1+ and L-selectin+ cells within the CX3CR1INT CD8+ 
T cell population compared to their CX3CR1NEG counterparts, 
indicating differential migratory and adhesive properties of 
these subsets (CX3CR1NEG versus CX3CR1INT ICAM-1: 68.4 
versus 47.1%, p = 0.02, L-selectin: 60.4 versus 35.4%, p = 0.02, 
Figure 5C).
increased l-selectin surface expression 
Follows Fractalkine-Mediated cX3cr1 
endocytosis on cD8+ T cells
To simulate the high fractalkine levels in the omental microen-
vironment and examine whether this affects adhesion molecule 
expression and memory phenotype; fractalkine treatment of 
peripheral blood T cells from three donors was performed for 
24 h. Fractalkine treatment induced a significant increase in sur-
face expression of L-selectin but not ICAM-1 on CD8+ T cells 
following 24 h, indicating that it alters their adhesiveness and 
lymphoid tissue homing capacity (L-selectin: 24.6 versus 35.5%, 
p < 0.05, Figure 6A). Fractalkine treatment had no significant 
effects on ICAM-1, LFA-1, VLA-4, or integrin alpha4 and beta7 
surface expression or memory phenotype of CD8+ T  cells 
defined by CD45RA and CD27 expression (Figures 6B–D). In 
data not shown, 24 h fractalkine treatment had no significant 
effects on pro-inflammatory cytokine production by the CD8+ 
T cells.
DiscUssiOn
high levels of soluble Fractalkine in 
Omentum can Drive T cell Migration and 
May represent a hallmark of Meta-
inflammation in Obesity-associated 
cancer Patients
For the first time, this study has revealed significantly high 
levels of soluble fractalkine in the omental adipose tissue 
conditioned media (ACM) derived from patients with the 
obesity-associated cancer EAC. This is in line with previous 
observations of fractalkine enrichment in VAT (8). Known 
inducers of fractalkine include the inflammatory cytokines 
IFN-γ, TNF-α, and IL-1β (13). Such an abundance of fractalkine 
was unsurprising as we have reported enrichments of IFN-γ 
and TNF-α producing T cells together with secreted IL-1β in 
FigUre 5 | CX3CR1NEG and CX3CR1INT populations represent significantly different CD8+ T cells in the peripheral blood with significantly different memory 
phenotypes, L-selectin, and ICAM-1 expression. (a) Bar charts showing the frequencies of naive, central memory, effector memory, and terminally differentiated 
CD8+ T cells, characterized by CD45RA and CD27 expression within the CX3CR1NEG and CX3CR1INT populations in peripheral blood of six non-cancer controls. (B) 
Bar chart showing frequencies of peripheral blood-derived CD8+ T cells expressing CD45RA (top) and CD27 (bottom) within CX3CR1NEG and CX3CR1INT populations 
(n = 3). (c) Bar chart showing frequencies of peripheral blood-derived CD8+ T cells ICAM-1 and L-selectin within CX3CR1NEG and CX3CR1INT populations (n = 3). 
p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t tests.
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the omentum of EAC patients (13, 22, 23). Interestingly, signifi-
cantly higher fractalkine levels were observed in the patients 
with highest serum CRP levels, which is indicative of its role in 
meta-inflammation and in line with previous reports of the cir-
culating levels of CRP and fractalkine in metabolic dysfunction 
(7, 27). However, this is the first reported association of high 
fractalkine in the omentum and high serum CRP in obesity-
associated cancer. Soluble fractalkine levels were significantly 
high in both obese and non-obese omentum in both cancer 
and non-cancer subjects. Furthermore, soluble cues from both 
obese and non-obese and both cancer and non-cancer omental 
microenvironments drove T cell migration suggesting that this 
tissue is a rich source of this chemokine and recruits significant 
numbers of T cells, regardless of obesity status. Interestingly, 
while fractalkine was secreted in abundance in the omentum 
and could drive in  vitro EAC-derived T  cell migration, this 
was not paralleled by high frequencies of T  cells expressing 
its specific receptor in this tissue. In fact, the highest propor-
tions of CX3CR1INT cells were identified in circulating CD8+ 
T  cell populations and not the omentum. Such frequencies 
were still significantly lower than CD8+ T cell frequencies in 
non-cancer controls suggesting that the fractalkine:CX3CR1 
axis might be perturbed by malignancy in this study cohort. 
Together with our previously reported data, our investigations 
suggest that fractalkine together with MIP-1α in the omentum 
recruit inflammatory T cells to this tissue in EAC, most likely 
FigUre 6 | The fractalkine-mediated CX3CR1INT to CX3CR1NEG conversion of CD8+ T cells is followed by enhanced L-selectin expression. (a) Bar charts showing 
frequencies of peripheral blood-derived CD8+ T cells expressing L-selectin (top) and ICAM-1 (bottom) following treatment with M199 media alone (untreated, black) 
or 30 ng/ml of recombinant fractalkine for 24 h (fractalkine, white pattern) (n = 6). (B) Bar chart (top) showing frequencies of peripheral blood-derived CD8+ T cells 
expressing alpha4 and beta7 integrins following treatment with M199 media alone (untreated, black) or 30 ng/ml of recombinant fractalkine for 24 h (fractalkine, 
white pattern) (n = 6). (B) Bar chart (bottom) showing frequencies of peripheral blood-derived CD8+ T cells expressing LFA-1 and VLA-4 following treatment with 
M199 media alone (untreated, black) or 30 ng/ml of recombinant fractalkine for 24 h (fractalkine, white pattern) (n = 6). (c) Bar chart showing the frequencies of total 
CD45RA+ and CD27+ populations of CD8+ T cells following treatment with M199 media alone (untreated, black) or 30 ng/ml of recombinant fractalkine for 24 h 
(fractalkine, white pattern) (n = 6). (D) Bar chart showing the frequencies of naive, effector memory, central memory, and terminally differentiated CD8+ T cells, 
characterized by CD45RA and CD27 expression following treatment with M199 media alone (untreated, black) or 30 ng/ml of recombinant fractalkine for 24 h 
(fractalkine, white pattern) (n = 6). *p < 0.05 by paired t tests.
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contributing to the pathological adipose tissue inflammation 
at the expense of effective anti-tumor immunity (19). As other 
studies have shown that fractalkine serves distinctive roles in 
different inflammatory diseases such as diabetes, dermatitis, 
asthma, and neuropathic pain, we propose that it may also 
serve functions additional to T cell chemotaxis in the omentum 
of EAC patients (8, 11, 12, 28).
Diminished Frequencies of cX3cr1+ 
cD8+ T cells and increased Frequencies 
of cX3cr1neg cD8+ T cells in Omentum 
are indicative of Fractalkine-Mediated 
cX3cr1inT to cX3cr1neg conversion
Our data reveal significantly higher proportions of CX3CR1HI 
and CX3CR1INT CD8+ T cells in the peripheral blood of EAC 
patients and significantly diminished frequencies in the 
omentum. CX3CR1HI and CX3CR1INT CD8+ T cells represent 
two of three distinct memory CD8+ T cell subsets which have 
recently been defined by their CX3CR1 expression (5). This 
classification includes a central memory CX3CR1NEG popula-
tion that expresses higher levels of L-selectin and is more 
prevalent in the lymphoid tissue, a CX3CR1INT population that 
expresses lower levels of L-selectin and circulates between the 
peripheral tissue and the blood, and a CX3CR1HI population 
that lacks L-selectin and the migratory capacity of the other 
populations and is predominantly effector memory/terminally 
differentiated in phenotype (5). CX3CR1INT CD8+ T cells have 
been described as peripheral memory T cells (5). They undergo 
more homeostatic divisions than any other memory subset to 
maintain self-renewal and can also convert to CX3CR1NEG to 
feed the central memory pool of CD8+ T  cells (5). However, 
the trigger or mediators for such transition have not been 
previously identified. To date, few studies have looked at the 
tissue localization of CX3CR1+ CD8+ T cell populations with 
recent reports of their migration to lymph nodes, spleen, bone 
marrow, lung, and liver in murine models of viral infection (5, 
29). Here, treatment of peripheral blood CD8+ T cells with the 
CX3CR1 ligand fractalkine resulted in significant reduction 
in their CX3CR1 surface expression and thus expanded the 
CX3CR1NEG pool of CD8+ T  cells. Due to the abundance of 
fractalkine in the omentum and due to previous reports that 
CX3CR1INT CD8+ T cells can replenish the CX3CR1NEG CD8+ 
T  cell pool, we propose that fractalkine recruits circulating 
T cells to omentum and subsequently mediates the conversion 
from CX3CR1INT CD8+ T cells to CX3CR1NEG CD8+ T cells, thus 
implicating the omentum as a key site in the accumulation of the 
memory CD8+ T cell pool in EAC and potentially other condi-
tions. While CX3CR1 is the specific receptor for fractalkine, it 
must be noted that Eotaxin-3 (CCL26) has been identified as 
a functional chemoattractant for CX3CR1+ CD8+ T cells (30). 
However, our data have revealed that EAC omentum is not an 
abundant source of Eotaxin-3 (data not shown), compared to 
chemokines such as MIP-1α and fractalkine thus reducing the 
likelihood of this chemokine governing CX3CR1+ CD8+ T cell 
trafficking to omentum in EAC.
Fractalkine Mediates cX3cr1inT to 
cX3cr1neg conversion in Peripheral 
Blood-Derived cD8+ T cells via receptor 
endocytosis
CX3CR1 has recently been identified as a marker of CD8+ T cell 
memory during viral infection in murine models but the role if 
any of fractalkine in the differentiation of such T cells has not 
been described (5). Here, a significant decrease in CX3CR1 
surface expression following fractalkine treatment was observed 
in the CD8+ T cell compartment in the peripheral blood but not 
in the T  cell populations containing lower levels of CX3CR1 
expression; circulating CD4+ T cells or omental CD4+ or CD8+ 
T  cells. Such cell type- and compartment-specific cell surface 
regulation of a chemokine receptor is not unique to CX3CR1 and 
similar findings have been reported with CXCR4 (31). Indeed, 
the internalization of CXCR4 facilitated its association with the 
T cell receptor and enhanced co-stimulation of cytokine produc-
tion by T  cells thus emphasizing the multifaceted functions of 
chemokines in immunity (3). Further work performed in this 
study has revealed that the reduction in CX3CR1 expression is 
due to endocytosis in line with previous reports on macrophages 
in sepsis patients (32). To our knowledge, this is the first report 
of CX3CR1 endocytosis on CD8+ T cells following ligand bind-
ing and implicates fractalkine as master regulator of CX3CR1INT 
to CX3CR1NEG conversion. Such endocytosis is not followed by 
CX3CR1 recycling to surface within 48 h of ligand binding even 
when fractalkine is removed. Furthermore, fractalkine-mediated 
endocytosis of its receptor does not lead to increased levels of 
CX3CR1 shedding. In fact, our western blot data show that the 
protein accumulates within the cell and stimulation with an 
array of inflammatory cytokines simulating the soluble cues of 
an inflammatory microenvironment could not trigger its recy-
cling to the cell surface. These data suggest that fractalkine elicits 
significant and long-lasting changes in CD8+ T cells, which may 
culminate in their retention in the omentum.
enhanced l-selectin expression by 
Peripheral Blood-Derived cD8+ T cells 
Following Fractalkine-Mediated 
conversion From a cX3cr1inT to a 
cX3cr1neg Phenotype
An abundance of soluble ICAM-1 and L-selectin levels were 
detected in the omentum-derived ACM of EAC patients, sug-
gesting their shedding by cells in this inflamed tissue and may 
be indicative of their role in immune cell arrest and retention 
in the VAT. Significant higher frequencies of ICAM-1+ and 
L-selectin+ cells within the CX3CR1NEG CD8+ T cell population 
are also reported here. Since CX3CR1NEG CD8+ T  cells are the 
predominant subset within the omentum, our data suggest that 
such cells have altered adhesive and migratory properties and 
this may serve a function in retention within the omentum. 
Interestingly, our data also revealed significantly different 
memory phenotypes between the peripheral blood CX3CR1NEG 
and CX3CR1INT CD8+ T  cell subsets and such characteristics 
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have been previously described together with differences in their 
migratory properties and those of CX3CR1HI CD8+ T cells (5). 
Others have shown that CX3CR1INT CD8+ T  cells in mice can 
increase their L-selectin expression and convert to CX3CR1NEG 
CD8+ T  cells, unlike CX3CR1HI CD8+ T  cells (5). For the first 
time, we identify fractalkine as a mediator of increased L-selectin 
expression by peripheral blood CD8+ T cells following their frac-
talkine-mediated conversion from a CX3CR1INT to CX3CR1NEG 
phenotype and we propose that these sequenced alterations occur 
in the fractalkine-rich environment of the omentum changing 
the migratory properties of CD8+ T cells in EAC. While soluble 
fractalkine induces changes in L-selectin surface expression, that 
of ICAM-1, VLA-4, LFA-1, alpha-4, and beta-integrin together 
with memory phenotype are unchanged. Contrary to ICAM-1 
expression being highest within the CX3CR1NEG CD8+ T  cell 
population in blood, these data reveal that fractalkine-mediated 
conversion of CX3CR1INT to CX3CR1NEG CD8+ T  cells is not 
accompanied by an increase in ICAM-1 expression and this event 
may be mediated by another soluble factor. These data identify 
a novel role for fractalkine in the alteration of migratory and 
lymphoid tissue homing capacity of CD8+ T cells and align with 
previous reports of fractalkine and CX3CR1 regulating immune 
cell responses via distinct disease-dependent mechanisms (28, 
32). For instance, this chemokine axis promotes T cell survival in 
asthma, while it promotes T cell retention in inflamed skin in der-
matitis and plays a role in immune paralysis in sepsis (11, 28, 32). 
However, for the first time, this study identifies fractalkine as a 
player in T cell recruitment to omentum and a master regulator of 
CX3CR1 expression, CX3CR1INT to CX3CR1NEG conversion and 
L-selectin expression. Together with our previously published 
data, we propose that such alterations change the fate of CD8+ 
T  cell trafficking and CD8+ T  cell-mediated immunity in EAC 
and may lead to their retention in the fractalkine-rich omentum 
where they contribute to pathological inflammation to the detri-
ment of effective anti-tumor immunity.
cOnclUsiOn
Fractalkine-driven migration of T cells to omentum in EAC is 
likely to contribute to the CD8+ T cell-mediated adipose tissue 
inflammation previously demonstrated in these patients (22, 23). 
In pilot data not shown, we have also found lower levels of soluble 
fractalkine in tumor compared to omentum in our patient cohort. 
Since the fractalkine:CX3CR1 pathway has been shown to have a 
selective bias for cytotoxic lymphocytes such as CD8+ T cells and 
NK cells, the preferential migration of CD8+ T cells to omentum 
over tumor might be detrimental for anti-tumor immunity in 
EAC and other obesity-associated cancers (33). Antagonizing 
the CX3CR1:fractalkine pathway might attenuate CD8+ T cell-
mediated inflammation in the omentum but secondary to this it 
might prevent the CX3CR1INT to CX3CR1NEG conversion and dis-
rupt frequencies and migration of peripheral and central memory 
CD8+ T  cells, which would also be detrimental to anti-tumor 
immunity. Therefore, our findings place fractalkine as more than 
a chemotactic cytokine driving T cell-mediated inflammation in 
EAC. Further in vivo work will be necessary to elucidate the con-
sequences of blocking this pathway in obesity-associated cancer. 
These novel data advance our knowledge on the multifaceted 
functionality of fractalkine and may inform T cell therapies and 
chemokine-targeted therapies in the future.
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